Viewing data from:

MULTIHANCE MULTIPACK

NDA

GADOBENATE DIMEGLUMINE | N021358 | BRACCO DIAGNOSTICS INC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part B Spending

CMS physician-administered drug spending for Multihance Multipack (2023)

Total Spending

$135K

Total Claims

5,681

Beneficiaries

5,094

ASP Price

—

HCPCS: A9578 — Injection, gadobenate dimeglumine (multihance multipack), per ml

Source: CMS Medicare Part B Spending by Drug (2023). Shows physician-administered drug costs.

Approval Letters

15 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 26.45GM/50ML (529MG/ML)

RLD

0 patents0 exclusivities▴

INJECTABLE;INTRAVENOUS | Approved: Nov 23, 2004

No patent or exclusivity listings for this strength.

#002 — 52.9GM/100ML (529MG/ML)

RLD

0 patents0 exclusivities▾

INJECTABLE;INTRAVENOUS | Approved: Nov 23, 2004